Barclays PLC Catalent, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Catalent, Inc. stock. As of the latest transaction made, Barclays PLC holds 4,284,643 shares of CTLT stock, worth $272 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares

4,284,643

Previous 4,284,643 -0.0%

Holding current value

$272 Million

Previous $260 Million -0.0%

% of portfolio

0.07%

Previous 0.07%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	SELL	$56.16 - $60.96 $38.3 Million - $41.5 Million	-681,431 Reduced 13.72%	4,284,643 $260 Million
Q2 2024 Aug 14, 2024	BUY	$53.58 - $57.02 $10.7 Million - $11.4 Million	200,108 Added 4.2%	4,966,074 $279 Million
Q1 2024 May 15, 2024	BUY	$42.56 - $59.82 $44.4 Million - $62.4 Million	1,042,370 Added 27.99%	4,765,966 $269 Million
Q4 2023 Feb 15, 2024	SELL	$32.18 - $46.57 $34.6 Million - $50 Million	-1,074,122 Reduced 22.39%	3,723,596 $167 Million
Q3 2023 Nov 07, 2023	BUY	$44.2 - $50.2 $62.4 Million - $70.9 Million	1,412,058 Added 41.71%	4,797,718 $218 Million
Q2 2023 Aug 03, 2023	BUY	$31.86 - $67.26 $92.6 Million - $195 Million	2,906,209 Added 606.15%	3,385,660 $147 Million
Q1 2023 May 04, 2023	BUY	$45.44 - $74.26 $9.57 Million - $15.6 Million	210,554 Added 78.3%	479,451 $31.5 Million
Q4 2022 Feb 13, 2023	BUY	$41.39 - $81.0 $2.92 Million - $5.72 Million	70,639 Added 35.63%	268,897 $12.1 Million
Q3 2022 Nov 03, 2022	BUY	$72.36 - $113.1 $5.26 Million - $8.22 Million	72,686 Added 57.88%	198,258 $14.3 Million
Q2 2022 Aug 12, 2022	SELL	$87.2 - $114.05 $8.65 Million - $11.3 Million	-99,177 Reduced 44.13%	125,572 $13.5 Million
Q1 2022 May 16, 2022	SELL	$94.19 - $124.49 $6.81 Million - $9 Million	-72,264 Reduced 24.33%	224,749 $24.9 Million
Q4 2021 Feb 14, 2022	BUY	$119.57 - $139.07 $3.29 Million - $3.83 Million	27,536 Added 10.22%	297,013 $38 Million
Q3 2021 Nov 09, 2021	SELL	$109.17 - $142.35 $516,919 - $674,027	-4,735 Reduced 1.73%	269,477 $35.9 Million
Q2 2021 Aug 13, 2021	BUY	$100.34 - $115.69 $1.17 Million - $1.35 Million	11,628 Added 4.43%	274,212 $29.6 Million
Q1 2021 May 13, 2021	BUY	$101.51 - $125.27 $11.5 Million - $14.2 Million	113,476 Added 76.1%	262,584 $27.7 Million
Q4 2020 Feb 11, 2021	BUY	$85.88 - $105.36 $1.39 Million - $1.71 Million	16,184 Added 12.18%	149,108 $15.5 Million
Q3 2020 Nov 12, 2020	BUY	$72.74 - $92.5 $2.4 Million - $3.06 Million	33,054 Added 33.1%	132,924 $11.4 Million
Q2 2020 Aug 12, 2020	BUY	$48.02 - $79.04 $451,291 - $742,817	9,398 Added 10.39%	99,870 $7.32 Million
Q1 2020 May 13, 2020	BUY	$36.95 - $62.95 $1.99 Million - $3.38 Million	53,769 Added 146.5%	90,472 $4.7 Million
Q4 2019 Feb 10, 2020	SELL	$47.06 - $56.64 $1.57 Million - $1.88 Million	-33,261 Reduced 47.54%	36,703 $2.07 Million
Q3 2019 Nov 14, 2019	BUY	$47.45 - $58.05 $2.32 Million - $2.84 Million	48,911 Added 232.32%	69,964 $3.33 Million
Q2 2019 Aug 14, 2019	SELL	$39.26 - $54.21 $756,383 - $1.04 Million	-19,266 Reduced 47.78%	21,053 $1.14 Million
Q1 2019 May 15, 2019	BUY	$29.84 - $43.92 $785,209 - $1.16 Million	26,314 Added 187.89%	40,319 $1.64 Million
Q4 2018 Feb 14, 2019	SELL	$29.95 - $46.34 $1.02 Million - $1.58 Million	-34,100 Reduced 70.89%	14,005 $436,000
Q3 2018 Nov 14, 2018	SELL	$40.12 - $45.55 $3.86 Million - $4.38 Million	-96,204 Reduced 66.67%	48,105 $2.19 Million
Q2 2018 Aug 14, 2018	BUY	$38.72 - $42.52 $4.08 Million - $4.48 Million	105,409 Added 270.97%	144,309 $6.05 Million
Q1 2018 May 15, 2018	BUY	$39.4 - $47.39 $688,987 - $828,708	17,487 Added 81.67%	38,900 $1.6 Million
Q4 2017 Feb 14, 2018	BUY	$37.27 - $43.02 $645,889 - $745,536	17,330 Added 424.44%	21,413 $880,000
Q3 2017 Nov 14, 2017	BUY	$33.75 - $41.67 $137,801 - $170,138	4,083	4,083 $163,000

Others Institutions Holding CTLT

# of Institutions

514

Shares Held

149M

Call Options Held

575K

Put Options Held

2.03M

View Full List

About Catalent, Inc.

Ticker CTLT
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 179,896,000
Market Cap $11.4B
Description
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products,...

More about CTLT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account